(Adnkronos Health) – “Italy today boasts a position of European leadership in the pharmaceutical sector. Ensuring regulatory certainty, timelines, and system predictability is a priority to continue on this path, in an era where investments move rapidly and where health and industrial policies, access to care, and competitiveness move within the same strategic space – stated Paolo Daniele Siviero, Director of Access and Regulatory Strategies at Farmindustria – The priorities to address are reducing payback costs, now at unsustainable levels, and accelerating access times, to bring innovation to patients as quickly as possible. Italy has skills, research, and production capacity of absolute excellence: the challenge is to ensure that, in global competition, it continues to be chosen for new investments.” However, the competitiveness of the pharmaceutical system also depends on the ability to preserve and strengthen the national production fabric, ensuring the availability of medicines and the security of supplies. This is an increasingly central theme in the European debate on the resilience of strategic supply chains.
“We cannot continue to consider price as the sole criterion for the sustainability of the pharmaceutical system. It is no coincidence that Europe, through the Critical Medicines Act, has identified as priorities the strengthening of continental production, the diversification of supply sources, and the prevention of essential medicine shortages – stated Michele Uda, General Director of Egualia – But while Europe focuses on supply security and purchasing policies that also value production reliability, Italy continues to burden companies that guarantee these medicines with undifferentiated payback. Incentives for new investments are important, but they are not enough if, in the meantime, we do not create the conditions to maintain existing productions. Without industrial sustainability, we risk losing strategic production capacity, increasing dependence on foreign countries, and exacerbating shortages. Equivalents and biosimilars represent a fundamental resource for the National Health Service, and only by guaranteeing a competitive but economically sustainable market can we continue to expand access to care, free up resources for innovation, and strengthen the country’s health security.”
Issues such as system sustainability and supply security inevitably intertwine with those of access to care and the concrete experience of patients. “The true test of the pharmaceutical legislation reform – specified Maria Vitale, Head of Health Programs at Cittadinanzattiva – will be its tangible impact on people’s daily lives. From our observatory, we see where the right to care weakens: when access to a treatment requires different times from one Region to another, when the therapeutic plan expires before the renewal visit, when the patient has to go from one pharmacy to another to find the medicine, when drug shortages interrupt the therapeutic paths of the most fragile patients. Proximity must be a central priority of the Unified Text: bringing care closer to where citizens live, strengthening territorial facilities even in internal and rural areas, and using data interoperability to connect the nodes of the professional network, overcoming fragmentation between doctors and local pharmacies. The sharing of clinical information and real-time stock monitoring should not only serve for planning or expenditure control purposes, but to constantly synergize caregivers to ensure therapeutic adherence, treatment safety, and timely availability of medicines. We ask that civic organizations and patient associations be involved from the preliminary phase of legislative decrees. The experience of those facing these obstacles must contribute to defining the measures and verifying if they truly reduce waiting times, avoidable travel, and therapy interruptions.”